Opinion|Videos|December 17, 2024
Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.
Advertisement
Episodes in this series
- Briefly describe the abstract “Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and what are the clinical implications in utilizing inhaled treprostinil compared with intravenous or subcutaneous treprostinil for connective tissue disease-associated PAH?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Virtual Reality Intervention Increased Empathy for Patients With MG
2
ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care
3
Mental Health Distress in Nonmelanoma Skin Cancer Largely Driven by Sociodemographic, Comorbid Factors
4
Strong Patient–Doctor Communication Improves Glaucoma Care: Ariana Levin, MD
5
